US 11,965,032 B1
Anti-CD20 antibody compositions
George Costas Avgerinos, Sudbury, MA (US); Patrick Michael Hossler, Westborough, MA (US); Jill A. Myers, Brookline, MA (US); and Yune Z. Kunes, Cambridge, MA (US)
Assigned to TG Therapeutics, Inc., New York, NY (US); and Laboratoire Francais du Fractionnement et des Biotechnologies, Les Ulis (FR)
Filed by TG Therapeutics, Inc., New York, NY (US); and Laboratoire Francais Du Fractionnement Et Des Biotechnologies, Les Ulis (FR)
Filed on Feb. 10, 2023, as Appl. No. 18/167,631.
Claims priority of provisional application 63/347,852, filed on Jun. 1, 2022.
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2887 (2013.01) [A61K 2039/505 (2013.01); C07K 2317/41 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
 
1. A single batch preparation of a population of anti-CD20 antibody proteins, wherein the anti-CD20 antibody proteins in the population are expressed from one or more nucleic acid sequences encoding a heavy chain comprising the amino acid sequence of SEQ ID NO:1 and a light chain comprising the amino acid sequence of SEQ ID NO:2, wherein the population of anti-CD20 antibody proteins has an N-glycan profile comprising 10 to 20% galactosylated glycans and 20 to 40% fucosylated glycans, and wherein the population of anti-CD20 antibody proteins is produced in a 15,000 L or 20,000 L bioreactor.